Skip to main content

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES)

  • P/E: N/A
  • GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67
  • SECTOR: ENERGY MINERALS
  • ASSETS-LIABILITIES: 1.58
  • DIVIDEND: .04%

Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth.
This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnings release.
According to Forbes, Pioneer is the 4th-largest producer of oil and gas in the United States. Pioneer has an EBITDA slightly below average for the largest 10 producers, however. However, Pioneer is cutting costs and increasing production, according to its Q4 earnings release, signaling that the company's business practices are improving.
In conclusion, my research of Pioneer has revealed that the company is improving, and has an impressive volume of production, while it does not have as good of margins as other comparable companies. Pioneer has posted a significant year-over-year gain in its last comparable quarter, and has a clean balance sheet. The company is steadily increasing is assets, finds itself located in the largest oil-producing region in the country, and has a track record of achieving very profitable years in the past.


SOURCES:







Labels:

Comments

  1. FactsMay 2, 2017 at 12:36 PM

    lol, profits? They lost money last qtr and the qtr before that and the qtr before that....
    I guess if you disregard all costs and capital raises they may have profited. Are you in the business of alternate facts?

    ReplyDelete

Post a Comment

Popular posts from this blog

ISRG STOCK WRITE UP

ISRG (INTUITIVE SURGICAL INC) P/E: 48 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $1.13 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 7.05 DIVIDEND: none ISRG is the ticker for Intuitive Surgical Inc, a company endeavoring in the manufacture and distribution of robotic surgical devices. The company recently gained FDA approval for a lower-cost device. They have a clean balance sheet with a history of upside surprises against earnings expectations, and report again 7/20/17. Revenues increased nearly 14%, while EPS increased 32% compared to the Q1 '16 results. While liabilities decreased on a year-over-year basis, assets decreased by a larger margin. R&D spending increased 36%, and administrative costs rose 16%. Taxes were cut in half, although the revenues increased, due to modified accounting principles, and tax benefits for the employee share-based compensation.. The ratio of assets-liabilities decreased from 9.14 to 7.05, which is...
1 comment
Read more

AMGN STOCK WRITE UP

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...
Post a Comment
Read more